How to buy Protagonist Therapeutics stock

Protagonist Therapeutics, Inc is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 76 staff and has a trailing 12-month revenue of around USD$25.7 million.

How to buy shares in Protagonist Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Protagonist Therapeutics. Find the stock by name or ticker symbol: PTGX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Protagonist Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Protagonist Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Protagonist Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Protagonist Therapeutics share price

Use our graph to track the performance of PTGX stocks over time.

Protagonist Therapeutics shares at a glance

• Key figures

Information last updated 2020-11-17.

52-week range	USD$5.3 - USD$23.43
50-day moving average	USD$20.7514
200-day moving average	USD$18.2497
Wall St. target price	USD$31.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.742

Buy Protagonist Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Protagonist Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Protagonist Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protagonist Therapeutics financials

Revenue TTM	USD$25.7 million
Gross profit TTM	USD$231,000
Return on assets TTM	-21.17%
Return on equity TTM	-48.89%
Profit margin	-252.03%
Book value	$4.545
Market capitalisation	USD$835.1 million

TTM: trailing 12 months

Shorting Protagonist Therapeutics shares

There are currently 2.5 million Protagonist Therapeutics shares held short by investors – that's known as Protagonist Therapeutics's "short interest". This figure is 7.1% down from 2.7 million last month.

There are a few different ways that this level of interest in shorting Protagonist Therapeutics shares can be evaluated.

Protagonist Therapeutics's "short interest ratio" (SIR)

Protagonist Therapeutics's "short interest ratio" (SIR) is the quantity of Protagonist Therapeutics shares currently shorted divided by the average quantity of Protagonist Therapeutics shares traded daily (recently around 315120.2970297). Protagonist Therapeutics's SIR currently stands at 8.08. In other words for every 100,000 Protagonist Therapeutics shares traded daily on the market, roughly 8080 shares are currently held short.

However Protagonist Therapeutics's short interest can also be evaluated against the total number of Protagonist Therapeutics shares, or, against the total number of tradable Protagonist Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protagonist Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Protagonist Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0757% of the tradable shares (for every 100,000 tradable Protagonist Therapeutics shares, roughly 76 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Protagonist Therapeutics.

Find out more about how you can short Protagonist Therapeutics stock.

Protagonist Therapeutics share dividends

We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.

Protagonist Therapeutics share price volatility

Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $5.3 up to $23.43. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 1.5328. This would suggest that Protagonist Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Protagonist Therapeutics overview

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.

Frequently asked questions

• What percentage of Protagonist Therapeutics is owned by insiders or institutions?

  Currently 1.382% of Protagonist Therapeutics shares are held by insiders and 97.796% by institutions.

• How many people work for Protagonist Therapeutics?

  Latest data suggests 76 work at Protagonist Therapeutics.

• When does the fiscal year end for Protagonist Therapeutics?

  Protagonist Therapeutics's fiscal year ends in December.

• Where is Protagonist Therapeutics based?

  Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560

• What is Protagonist Therapeutics's ISIN number?

  Protagonist Therapeutics's international securities identification number is: US74366E1029

• What is Protagonist Therapeutics's CUSIP number?

  Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102